Your Global Leader in Stem Cell Market Research
The Cymerus™ technology is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company. The Cymerus™ technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs), and subsequently, for differentiating the cells into mesenchymal stem cells (MSCs). [Read more…]
December 04, 2017, GOSSELIES, Belgium—Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809). The financial terms of the agreements are not disclosed. [Read more…]
iPSC research is on the rise with more than 14,701 publications released about the cell type on PubMed.gov, the world’s leading database of scientific publications. Induced pluripotent stem cells (iPSCs) are differentiated cells that are reprogrammed back into an embryonic-like state. To understand the competitive nature of the iPSC research products market, it is important to consider the degree of competition that has entered the market since the discovery of the cell type in 2006.
There are now more than 40 companies offering iPSC research products. The change in the number of companies offering iPSC research products increased substantially from 2013 to 2014, because there were 31 companies offering iPSC research products in 2013, and that number increased to 40 by 2014. In 2015, Pluriomics was a notable newcomer to the iPSC products scene. By 2017, Pluriomics and Axiogenesis merged to become Ncardia.
Other industry acquisitions that merged providers of iPSC research products include Thermo Fisher Scientific’s acquisition of Life Technologies Corporation on February 3, 2014, and ReproCELL’s acquisition of Stemgent, Inc., on September 9, 2014.
In September 2017, Axiogenesis AG and Pluriomics B.V. combined forces to create Ncardia, a global authority in cardiac and neural applications of human induced pluripotent stem cells (iPSCs).
ReproCELL was established in 2009 as a venture company originating from the University of Tokyo and Kyoto University and was the first company to launch a commercial iPSC product. It released a human iPSC-derived cardiomyocyte product, called “ReproCario.” [Read more…]
Founded in 2007 by Rudolf Jaenisch with backing from Arch Venture Partners, Fate Therapeutics’ corporate headquarters are in San Diego, California. It also has a subsidiary in Ottawa, Canada. Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators and biologic or small molecule compounds that guide cell fate. [Read more…]
Since the discovery of induced pluripotent stem cells in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the stem cell type. In addition to this important basic research, a great deal of applied (“translational”) results has been done with the cell type. Induced pluripotent stem cells (also called iPS cells or iPSCs) are revolutionizing regenerative medicine because they represent a potential route for producing patient-specific stem cells for research or clinical use.
In the future, iPS cells will facilitate progress in personalized medicine by allowing a patient to use his or her own cells. In addition, iPSCs also show great promise in other areas, such as phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs under development, in short, facilitating the study of a “disease in a dish.”
